文献速递血液净化与透析肾血管病与高血压

蔗糖铁与透析中血压的关联

Associations of Iron Sucrose and Intradialytic Blood Pressure.
PubMed 文献 · Am J Kidney Dis · 2022-12-29

这项前瞻性队列研究纳入950例维持性血液透析门诊患者,评估透析中给予蔗糖铁与透析中低血压、高血压及收缩压参数的关联。调整模型显示,较高剂量蔗糖铁与透析中低血压发生率降低11%相关,同时与透析中高血压风险升高相关。

要点

  • 蔗糖铁≥100mg相比0mg,透析中低血压发生率比为0.89(95%CI 0.85-0.94)。
  • 蔗糖铁≥100mg相比0mg,透析中高血压发生率比为1.07(95%CI 1.04-1.10)。
  • 研究观察到蔗糖铁与透析中及透析后收缩压升高相关。

核心结论

  • 研究观察到透析中静脉给予蔗糖铁与透析中低血压风险降低及透析中高血压风险升高存在独立关联。
  • 需要未来研究更好地理解这些关联背后的机制。

研究设计与样本

  • 前瞻性队列研究,纳入950例接受维持性血液透析的门诊患者。
  • 暴露为透析中给予蔗糖铁,结局为透析中低血压、透析中高血压及收缩压参数。
  • 分析采用未调整和调整的泊松回归及线性重复测量回归模型。

主要发现

  • 患者平均年龄53±22岁,43%为女性,38%为黑人,透析前平均收缩压为152±26(标准差)mm Hg。
  • 基线时,接受较高剂量蔗糖铁的患者相比未接受蔗糖铁者更倾向于患有糖尿病、透析时间更长、促红细胞生成素刺激剂使用频率更高。
  • 调整模型中,较高剂量蔗糖铁与透析中低血压发生率降低11%相关(蔗糖铁≥100mg vs 0mg的 incidence rate ratio [IRR] 为0.89 [95%CI 0.85-0.94])。
  • 调整分析中,透析中给予较高剂量蔗糖铁与透析中高血压相关(蔗糖铁≥100mg vs 0mg的IRR为1.07 [95%CI 1.04-1.10])。
  • 研究观察到蔗糖铁给药与透析中及透析后收缩压升高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无法获得精确的蔗糖铁制剂(体积)信息。
  • 无法获得每次透析的实验室数据。
  • 无法获得门诊用药信息。
  • 本研究未记录容量状态的客观指标、家庭用药及症状数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Intradialytic hypotension and intradialytic hypertension are associated with morbidity and mortality in hemodialysis (HD). Many factors can contribute to intra-HD blood pressure (BP) changes, such as drugs with vasoactive properties that can destabilize an already tenuous BP. Intravenous iron sucrose is commonly administered to correct iron deficiency; however, its reported associations with altered hemodynamics have not been consistent. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 950 outpatients receiving maintenance HD. EXPOSURE: Iron sucrose administered during HD. OUTCOME: Intradialytic hypotension, intradialytic hypertension, systolic blood pressure parameters. ANALYTICAL APPROACH: Unadjusted and adjusted Poisson and linear repeated measures regression models. RESULTS: The mean age of patients included in the study was 53±22 years, 43% were female, and 38% were Black. Mean pre-HD SBP was 152±26 (SD) mm Hg. At baseline, the patients who received higher doses of iron sucrose tended to have diabetes, have longer HD sessions, and have a higher frequency of erythropoiesis-stimulating agent use, compared with those who did not receive iron sucrose. In adjusted models, higher doses of iron sucrose were associated with an 11% lower rate of intradialytic hypotension (incidence rate ratio [IRR] for iron sucrose≥100mg vs 0 mg, 0.89 [95% CI, 0.85-0.94]). In adjusted analyses, the administration of higher doses of iron sucrose during HD was associated with intradialytic hypertension (IRR for iron sucrose≥100mg vs 0 mg, 1.07 [95% CI, 1.04-1.10]). LIMITATIONS: Nonavailability of the precise iron sucrose formulation (volume), laboratory data for each HD session, and outpatient medications. Objective measures of volume status, home medications, and symptom data were not recorded in this study. CONCLUSIONS: We observed an independent association of intravenous iron sucrose administration during HD with a lower risk of intradialytic hypotension and higher risk of intradialytic hypertension. Future studies to better understand the mechanisms underlying these associations are warranted. PLAIN-LANGUAGE SUMMARY: Intradialytic hypotension and intradialytic hypertension are common among patients on hemodialysis, and they are associated with morbidity and mortality. Although many factors may contribute to these risks, medications administered during hemodialysis play an important role. We studied the significance of the intravenous iron sucrose used to treat iron deficiency and the impact it may have on blood pressure during dialysis. In our study of 950 outpatient hemodialysis patients, we observed that administration of iron sucrose was associated with higher systolic blood pressure (during and after hemodialysis sessions) as well as a lower risk of intradialytic hypotension. We also observed that higher doses of iron sucrose are associated with the development of intradialytic hypertension.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Singh AT, Yen TE, Mothi SS, et al. Associations of Iron Sucrose and Intradialytic Blood Pressure. Am J Kidney Dis. 2022. PMID: 36587889. doi:10.1053/j.ajkd.2022.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。